Increased Overall Survival (OS) of patients with pancreatic cancer: results of a Phase III study of adjuvant mFOLFIRINOX presented at ASCO 2018

mFOLFIRINOX is a modified regimen containing Debiopharm’s Oxaliplatin, combined with, irinotecan, fluorouracil and leucovorin

Prof Thierry Conroy, medical oncologist and Director of the Institut de Cancerologie de Lorraine (Nancy, France), presented at ASCO 2018 the results of phase III study to compare adjuvant chemotherapy with gemcitabine versus mFolfirinox in patients with resected pancreatic adenocarcinomas.

The results showed a significant improvement of the OS and disease-free survival (DFS) and indicate that mFOLFIRINOX may become the new adjuvant standard of care for patients suffering from this debilitating disease.


Some key elements and finding

  • Numbers of patients: 493
  • Median follow-up was 33.6 months
  • Median DFS was 21.6 months ( vs. 12.8 months with gemcitabine)
  • Median OS was 54.4 months (vs. 35 months with gemcitabine)
  • Median time to metastases was 30.4 months (vs. 17 months with gemcitabine).


For more information